FMP
Indaptus Therapeutics, Inc.
INDP
NASDAQ
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
0.938 USD
0.048 (5.12%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Michael J. Newman Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://indaptusrx.comexchange
NASDAQ
Description
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
CIK
0001857044
ISIN
US45339J1051
CUSIP
45339J105
Address
3 Columbus Circle
Phone
347 480 9760
Country
US
Employee
7
IPO Date
Aug 4, 2015
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
INDP Financial Summary
CIK
0001857044
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
45339J105
ISIN
US45339J1051
Country
US
Price
0.94
Beta
1.13
Volume Avg.
114.63k
Market Cap
11.27M
Shares
-
52-Week
0.84-3.1
DCF
1.57
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.55
P/B
-
Website
https://indaptusrx.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest INDP News
It looks like there's no news available.
